# Population size, HIV prevalence, and antiretroviral therapy coverage among key

# 2 populations in sub-Saharan Africa: collation and synthesis of survey data 2010-2023

- <sup>3</sup> Oliver Stevens MPH<sup>§1</sup>, Keith Sabin PhD<sup>2</sup>, Rebecca Anderson BSc<sup>1</sup>, Sonia Arias Garcia
- <sup>4</sup> MSc<sup>2</sup>, Kalai Willis MSPH<sup>3</sup>, Amrita Rao PhD<sup>3</sup>, Anne F. McIntyre PhD<sup>4</sup>, Elizabeth Fearon
- <sup>5</sup> PhD<sup>5</sup>, Emilie Grard MPH<sup>1</sup>, Alice Stuart-Brown MSc<sup>1</sup>, Prof Frances Cowan MD<sup>6,7</sup>, Prof
- 6 Louisa Degenhardt PhD<sup>8</sup>, James Stannah MPH<sup>13</sup>, Jinkou Zhao PhD<sup>9</sup>, Avi J. Hakim
- <sup>7</sup> PhD<sup>4</sup>, Katherine Rucinski PhD<sup>3</sup>, Isabel Sathane BSc<sup>10</sup>, Makini Boothe PhD<sup>11</sup>, Lydia
- 8 Atuhaire PhD<sup>12</sup>, Prof Peter S. Nyasulu PhD<sup>12,13</sup>, Mathieu Maheu-Giroux ScD<sup>14</sup>, Prof
- <sup>9</sup> Lucy Platt PhD<sup>15</sup>, Brian Rice PhD<sup>16</sup>, Wolfgang Hladik MD<sup>4</sup>, Prof Stefan Baral MD<sup>3</sup>, Mary
- <sup>10</sup> Mahy ScD<sup>2</sup>, Jeffrey W. Imai-Eaton PhD<sup>1, 17</sup>
- <sup>11</sup> MRC Centre for Global Infectious Disease Analysis, School of Public Health, <sup>12</sup> Imperial College London, London, United Kingdom
- <sup>13</sup> <sup>2.</sup> Data for Impact, The Joint United Nations Program on HIV/AIDS (UNAIDS), Geneva,
   <sup>14</sup> Switzerland
- <sup>3.</sup> Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- <sup>4.</sup> US Centers for Disease Control and Prevention (CDC), Atlanta, USA
- <sup>5.</sup> Institute for Global Health, University College London, London, United Kingdom
- <sup>18</sup> <sup>6.</sup> Liverpool School of Tropical Medicine, Liverpool, United Kingdom
- <sup>19</sup> <sup>7</sup> Centre for Sexual Health and HIV/AIDS Research, Zimbabwe
- <sup>8</sup> National Drug & Alcohol Research Centre, University New South Wales, Sydney,
   Australia
- <sup>9.</sup> The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
- <sup>10.</sup> Ministry of Health, Maputo, Mozambique
- <sup>11.</sup> Data for Impact, The Joint United Nations Program on HIV/AIDS (UNAIDS), Maputo,
   Mozambique
- <sup>12.</sup> Division of Epidemiology & Biostatistics, Department of Global Health, Faculty of
   <sup>27</sup> Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- <sup>13.</sup> Division of Epidemiology & Biostatistics, School of Public Health, Faculty of Health
   Sciences, University of the Witwatersrand, Johannesburg, South Africa
- <sup>30</sup><sup>14.</sup> Department of Epidemiology and Biostatistics, School of Population and Global <sup>31</sup>Health, McGill University, Montréal, Canada
- <sup>15.</sup> Faculty of Public Health and Policy, London School of Hygiene and Tropical
   Medicine, London, United Kingdom

- <sup>16.</sup> Sheffield Centre for Health and Related Research (SCHARR), School of Medicine
   and Population Health, University of Sheffield, United Kingdom
- <sup>17.</sup> Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard
- T. H. Chan School of Public Health, Boston, MA, USA
- 38
- <sup>39</sup> § Correspondence to:
- 40 Oliver Stevens
- 41 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial
- 42 College London
- 43 St. Mary's Hospital Campus
- 44 Norfolk Place
- 45 London
- 46 W2 1PG
- 47 United Kingdom
- 48 <u>o.stevens@imperial.ac.uk</u>
- 49
- 50 Word count: 3790 / 3500
- 51 Abstract: 310 / 300

# 52 Abstract

Background: Key population HIV programmes in sub-Saharan Africa (SSA) require 53 epidemiologic information to ensure equitable and universal access to effective 54 services. We consolidated survey data among female sex workers (FSW), gay men and 55 other men who have sex with men (MSM), people who inject drugs (PWID), and 56 transgender people to estimate key population size, HIV prevalence, and antiretroviral 57 therapy (ART) coverage for countries in mainland SSA. 58 Methods: Key population size estimates (KPSE), HIV prevalence, and ART coverage 59 data from 39 SSA countries between 2010-2023 were collated from existing databases 60 and verified against source documents. We used Bayesian mixed-effects spatial 61 regression to model urban KPSE as a proportion of the gender/year/area-matched 15-62 49 years adult population. We modelled subnational key population HIV prevalence and 63

ART coverage with age/gender/year/province-matched total population estimates as
 predictors.

Findings: We extracted 2065 key population size, 1183 HIV prevalence, and 259 ART 66 coverage data points. Across national urban populations, a median of 1.65% of adult 67 cisgender women were FSW (interquartile range [IQR]=1.35-1.91%), 0.89% of men 68 were MSM (IQR=0.77-0.95%), 0.32% of men injected drugs (IQR=0.31-0.34%), and 69 0.10% of women were transgender (IQR=0.06-0.12%). HIV prevalence among key 70 populations was, on average, 4 to 6 times higher than matched total population 71 prevalence, and ART coverage was correlated with, but lower than, total population 72 ART coverage with wide heterogeneity in relative ART coverage across studies. Across 73

SSA, key populations were estimated as 1.2% (95% credible interval [Crl]: 0.9, 1.6) of
the total population aged 15-49 years but 6.1% (95% Crl: 4.5, 8.2) of people living with
HIV.

- <sup>77</sup> Interpretation: Key populations in SSA experience higher HIV prevalence and lower
- ART coverage, underscoring the need for focused prevention and treatment services. In
- <sup>79</sup> 2024, limited data availability and heterogeneity constrain precise estimates for
- <sup>80</sup> programming and monitoring trends. Strengthening key population surveys and routine
- data within national HIV strategic information systems would support more precise
- 82 estimates.
- **Funding:** UNAIDS, BMGF, NIH

#### **Research in Context** 84

93

#### Evidence before this study 85

Key populations, including female sex workers (FSW), gay men and other men who 86 have sex with men (MSM), people who inject drugs (PWID), and transgender people, 87 are at higher risk of HIV infection, including in sub-Saharan Africa (SSA). Delivering 88 appropriate HIV prevention and treatment services for key populations and monitoring 89 an equitable HIV response requires robust information on key population size. HIV 90 prevalence, the treatment cascade, and new HIV infections. For this reason, key 91 population surveys, including population size estimation and bio-behavioural surveys, 92 are a standard component of comprehensive national HIV surveillance.

Several complementary ongoing initiatives consolidate HIV data on key populations to 94 support programme planning and implementation, global advocacy, and research. 95 These include the Key Population Atlas and Global AIDS Monitoring (Joint United 96 Nations Programme on HIV/AIDS [UNAIDS]), databases maintained by the US Centers 97 for Disease Control and Prevention (CDC) and The Global Fund to Fight AIDS, 98 Tuberculosis and Malaria (The Global Fund), and the Global.HIV initiative (Johns 99 Hopkins University). These include similar data sources, but vary in scope, inclusion 100 criteria, data elements recorded, and linkage to and validation against primary source 101 reports. Incomplete recording of key methodological details limits appraisal and formal 102 evidence synthesis, and therefore utility of data for strategic planning. 103

Many other research studies have systematically reviewed, analysed, and extrapolated 104 key population survey data in sub-Saharan Africa in single countries or across multiple 105

106	countries. These studies have tended to focus on specific outcomes or population
107	groups of interest, and primarily comprise an appraisal of peer-reviewed literature.
108	Added value of this study
109	We consolidated and deduplicated data collected between 2010-2023 from existing key
110	population survey databases maintained by the UNAIDS Key Population Atlas, UNAIDS
111	Global AIDS Monitoring, US CDC, and the Global Fund. We obtained published and
112	grey literature surveillance reports from the Johns Hopkins University Global.HIV
113	repository, additional web-based searches, and engagement with country HIV strategic
114	information teams, and validated each observation of key population size, HIV
115	prevalence, or ART coverage against primary surveillance reports. We used regression
116	to characterise the relationship between key population and total population HIV
117	indicators and extrapolated key population size estimates (KPSE), HIV prevalence, and
118	ART coverage data to national-level estimates for all countries in mainland SSA.
119	This exercise was the most comprehensive effort to date to consolidate key population
120	HIV data in SSA. We analysed over 3000 observations from 126 KPSE, 217 HIV
121	prevalence, and 62 ART coverage studies. We estimated that across urban populations
122	aged 15-49 years in SSA countries, a median of 1.65% of cisgender women were FSW;
123	0.89% of men have sex with men; 0.32% of men injected drugs; and 0.10% of women
124	were transgender. This translated to 3.7 million FSW, 1.9 million MSM, 770,000 PWID,
125	and 230,000 transgender women (TGW) in SSA who require comprehensive HIV
126	prevention or treatment services. FSW, MSM, PWID, and TGW together were estimated
127	as 1.2% of the population aged 15-49 years, but comprised 6.1% of people living with

HIV. ART coverage among members of key populations living with HIV increased with
total population ART coverage, but was lower for all key populations. We identified large
gaps in data availability. Of the four key populations and three indicators studied, only
Mozambique had data for all twelve indicators. Data were particularly sparse for
transgender populations and PWID.

# 133 Implications of all the available evidence

Key populations experience higher HIV prevalence and lower ART coverage across all
 settings in sub-Saharan Africa than the total population. Extrapolated national estimates
 provide a foundation for planning appropriate key population-focused services for HIV
 prevention and treatment in all settings, including those with no or limited data.

However, large data availability gaps driven by discriminatory practices and punitive 138 policies against key populations, inconsistency of existing data, and consequent wide 139 uncertainty ranges around estimates limit the ability of existing data to guide granular 140 programmatic planning and target setting for key population services and to monitor 141 trends. More consistent surveillance implementation and improved routine surveillance 142 through HIV prevention and treatment programmes for key populations would support 143 monitoring equitable and equal programme access, as outlined in the Global AIDS 144 Strategy 2021-2026 developed by UNAIDS, its co-sponsors, and other partners to end 145 HIV/AIDS as a public health threat by 2030. 146

# 147 Introduction

Key populations, including female sex workers (FSW), gay men and other men who 148 have sex with men (MSM), people who inject drugs (PWID), and transgender people, 149 experience higher risk of acquiring and transmitting HIV due to a combination of 150 biological and sociostructural factors, including stigma and criminalisation.<sup>1-3</sup> The Global 151 AIDS Strategy 2021-2026 calls for "equitable and equal access" to HIV prevention and 152 treatment to reduce HIV incidence and end HIV/AIDS as a public health threat by 2030.<sup>4</sup> 153 Delivering evidence-based HIV services for key populations and monitoring attainment 154 of an equitable HIV response requires robust epidemiologic and service engagement 155 indicators, including key population size, HIV prevalence and incidence, treatment and 156 prevention cascades. 157

Key population survey data are sparse and less representative of their target population 158 than common general population sampling approaches such as national household 159 surveys or sentinel surveillance. Key population surveys often rely on respondent-driven 160 and venue-based sampling methods<sup>5,6</sup> which require strong assumptions to interpret as 161 population-representative. Household survey sampling frames are inappropriate for 162 reaching populations that are mobile and unlikely to disclose risk behaviour due to 163 societal marginalisation and discrimination.<sup>7–9</sup> Key population surveys are often 164 infrequent and commonly restricted to, or disproportionately conducted in, urban areas. 165

Systematic reviews and meta-analyses of population size, HIV prevalence, or
 antiretroviral therapy (ART) coverage encompassing sub-Saharan Africa (SSA) have
 been conducted for FSW,<sup>10,11</sup> MSM,<sup>12,13</sup> PWID,<sup>14,15</sup> and transgender women (TGW).<sup>16,17</sup>

Several independent initiatives have been undertaken to consolidate key population
 surveillance data.<sup>18–21</sup> These efforts aim to monitor the state of the epidemic, evaluate
 programmes, and make recommendations on key population data reporting and quality
 thresholds.

We consolidated and harmonised key population size estimates (KPSE), HIV
prevalence, and ART coverage data from existing databases and described data
availability across countries and over time for each key population. We characterised
the relationship between key population and total population HIV indicators and
extrapolated KPSE, HIV prevalence, and ART coverage data to national-level estimates
for mainland countries in SSA.

## 179 Methods

#### 180 Data sources and extraction

We consolidated data from studies conducted 2010-2023 from four existing databases 181 and two systematic reviews among FSW, MSM, PWID, and transgender people.<sup>13,22</sup> 182 Data among incarcerated people were not included as part of this review. The existing 183 databases were the Joint United Nations Programme on HIV/AIDS (UNAIDS) Global 184 AIDS Monitoring submissions,<sup>23</sup> UNAIDS Key Population Atlas,<sup>24</sup> the Global Fund to 185 Fight AIDS, Tuberculosis and Malaria (the Global Fund) surveillance database, and a 186 dataset maintained by the US Centers for Disease Control and Prevention (CDC) 187 Division of Global HIV & TB Key Population Surveillance Team (Supplementary Table 188 S1). For each observation, we extracted information about the study methodology, 189 study location (country, subnational location), study population gender and age group, 190

central estimate, sample size, standard error, and primary source or reference (e.g.,
 survey report) (Supplementary Table S2).

Source documents were compiled from archives accompanying each database, the 193 Johns Hopkins University Global. HIV document repository.<sup>25</sup> Medline, and Google 194 Scholar, following which we contacted UNAIDS Strategic Information advisors and other 195 HIV programme contacts in each country to seek missing reports. Four authors (OS, 196 RA, EG, AS-B) reviewed source documents to deduplicate observations recorded in 197 multiple databases, validate against sources, and extract missing data elements. During 198 source review, we added observations when additional relevant data were reported, or 199 additional sources were ascertained that were not in the initial databases. 200

Observations were excluded if: key population definition, year, or study area were 201 missing; the study area was non-specific (e.g., 'urban areas' or '5 provinces'); estimates 202 were modelled or extrapolated; or data could not be confirmed by primary source 203 review. There were no age group eligibility criteria for inclusion in analysis. Studies 204 were not excluded or differentiated in our analysis according to study-specific population 205 group definitions based on engaging in risk behaviours or time periods (e.g. sold sex in 206 the last 6 months versus last 12 months; Supplementary Text S1). Transgender men 207 (TGM) were not analysed or reported here due to insufficient data, but available 208 observations are included in supplementary datasets 209

210 (https://zenodo.org/records/10838438).

# 211 Data processing

212	To compare population sizes across settings, KPSE reported as counts were converted
213	to population proportions. Each KPSE was matched to the total population
214	denominator <sup>26-28</sup> by age, gender, year, and area, and assigned to one of seven method
215	categories <sup>29</sup> (Supplementary Text S2). Age information was missing from nearly all key
216	population reports; missing age ranges were assigned as age 15-49 years. Unless
217	gender was specified, PWID were assumed to be men as 90% of people who inject
218	drugs in sub-Saharan Africa are men. <sup>22</sup> Surveys among transgender people which did
219	not report gender were assumed to be among transgender women because
220	respondents often reported high prevalence of male partners and receptive anal
221	intercourse, and surveys among TGM in SSA remain rare. <sup>17</sup>
	Key perception LIV providence and ADT enverone chaet attacts were compared to total
222	Key population HIV prevalence and ART coverage observations were compared to total
223	population HIV prevalence or ART coverage, respectively, matched by age, gender,
224	year, and first administrative level (henceforth 'province'). Provincial age/gender-specific
225	HIV prevalence and ART coverage were extracted from UNAIDS Naomi subnational
226	estimates for 2022 and projected backwards 2000-2021 parallel to national HIV
227	prevalence and ART coverage trajectories among adults 15-49 years. <sup>30</sup> Only
228	serologically-determined HIV prevalence observations were included in analysis.
229	Key population ART coverage observations derived from populations with self-reported
230	HIV-positive status or clinic-based recruitment were excluded. ART usage was
231	determined through either self-report or laboratory methods via antiretroviral (ARV)
232	metabolite biomarker or viral load (VL) testing. Viral load suppression (VLS)

233	observations were standardised using a reporting threshold of 1000 copies/ml. <sup>31</sup> In
234	cases where surveys measured both ARV biomarker and VL, ARV biomarker was used
235	VLS observations were converted to estimates of ART coverage assuming a logit
236	difference of -0.32, the average difference from studies that measured both viral load
237	and metabolite-confirmed ARV status (Supplementary Text S3).

#### 238 Analysis

We used Bayesian mixed-effects linear regression to model logit-transformed KPSE 239 proportions among the urban total population aged 15-49 years at provincial level. 240 Separate regressions were estimated for each key population. The model included 241 effects for study method, spatially-correlated random effects between neighbouring 242 countries and provinces, and a study-level random effect allowing correlation among 243 KPSE proportions from the same study. Study method was classified as: (1) non-244 mapping-based empirical methods that estimated total key population size, or (2) 245 Priorities for Local AIDS Control Efforts (PLACE) or mapped estimates which counted 246 venue- or hotspot-attending population size (see Supplementary Text S2 for details). 247 Within these, method-specific random effects were included to permit empirical 248 deviations from the central estimate. National KPSE counts were extrapolated using 249 urban KPSE proportions, the proportion of the population living in urban areas,<sup>32</sup> and 250 the assumed rural-to-urban ratio of key population size. Qualitative data indicate that 251 KPSE proportions are higher in urban areas than rural areas, but no empirical data were 252 available to quantify the rural-to-urban ratio.<sup>33–35</sup> To reflect wide uncertainty in the rural-253 to-urban ratio, we assumed that rural KPSE proportions were, on average, 40% lower 254

12

~ 4

than in urban areas, but with a wide range such that 80% of the time the true value will
be between 20% and 60% lower.

For HIV prevalence, we modelled the relationship between logit-transformed key 257 population HIV prevalence and logit total population HIV prevalence (age 15-49 years). 258 FSW and PWID were modelled separately. Due to limited data, MSM and TGW were 259 modelled together, but with a population type fixed effect reflecting empirical prevalence 260 difference between TGW and MSM.<sup>17</sup> We modelled survey HIV prevalence 261 observations with a beta-binomial distribution to allow for overdispersion, accounting for 262 additional variation between populations and study designs. The model included fixed 263 effects for logit population prevalence interacted with region (Eastern and Southern 264 Africa [ESA] or Western and Central Africa [WCA]) and province-, country-, and study-265 level random effects. Country- and province-level random effects were spatially 266 correlated. 267

Primary analysis for key population ART coverage, was restricted to diagnostically-268 determined ART usage (either via ARV biomarker or VL testing). Logit-transformed key 269 population ART coverage was modelled as a function of logit total population ART 270 coverage in the same year, age group, and province. All key populations were modelled 271 together with random slopes for each key population to enable sharing of information 272 about the overall relationship for groups with very limited data. The observed number on 273 ART was modelled with a beta-binomial distribution with fixed effects for logit population 274 ART coverage, spatially correlated country- and province-level random effects, and 275 study-level random effects. 276

We conducted sensitivity analyses in which self-reported ART coverage data were also
included. For all three models (KPSE, prevalence, ART coverage) in sensitivity analysis
we used ages 15-29 years as the matched total population denominator for MSM and
TGW regression analyses, and 15-39 years for FSW, reflecting the younger median age
of survey respondents.<sup>36,3736–38</sup>

We combined national KPSE, HIV prevalence, and ART coverage estimates to 282 calculate the number of KPLHIV and on ART. Ninety-five percent credible intervals were 283 generated by combining 1000 posterior samples for each outcome. We calculated 1000 284 regional median KPSE differences from each of the posterior samples of national KPSE 285 proportions, and calculated 95% credible intervals by combining the 1000 regional 286 median differences. KPLHIV estimates were divided by estimates of the total PLHIV 287 aged 15-49 years from 2022 national UNAIDS estimates to calculate the proportion of 288 all PLHIV associated with each key population.<sup>39</sup> 289

Data were extracted, deduplicated, and validated in Microsoft Excel. Statistical analyses
 were conducted in R version 4.2.0 using the R-INLA package (v23.4.24). Further
 statistical methods details are in Supplementary Text S4. The GATHER reporting
 checklist<sup>40</sup> is in Supplementary Table S17.

### 294 Ethics statement

This study received ethical approval from the Imperial College Research Integrity and Governance Team (ICREC #6412027). Regulatory bodies providing ethical approvals or other ethics considerations for included studies are reported in Supplementary File S3.

## 298 Role of the funding source

Authors KS, SA-G, MB, and MM are employees of UNAIDS and contributed to the
 conceptualisation of the study, interpretation of results, and editing the manuscript. OS,
 RA, and JWI-E had access to all data included in the study. OS and JWI-E accepted
 responsibility to submit for publication.

#### 303 **Results**

- <sup>304</sup> 4542 KPSE conducted between 2010 to 2023 were compiled (Figure 1). Following data
- cleaning, source document review, and area matching, 2065 observations were
- <sup>306</sup> extracted from 126 studies (Table 1; Supplementary Figure S1). Data were most
- available for FSW (n=972, data from 35/39 countries; Supplementary Table S3),
- followed by MSM (n=647, 33/39 countries), PWID (n=329, 23/39 countries), TGW
- <sup>309</sup> (n=117, 13/39 countries), and TGM (n=16, 2/39 countries). Sixty-nine percent (445/647)
- of urban MSM population proportion observations were below 1% of the male adult (15-
- 49 years) population (Supplementary Figure S2).
- <sup>312</sup> We identified 2732 key population HIV prevalence estimates, from which 1183 were
- extracted from 217 studies after processing. Denominators were reported for 98%
- (1154/1183) of observations. Most data were available for FSW (n=559, 36/39)
- countries), followed by MSM (n=370, 34/39 countries), PWID (n=159 21/39 countries),
- <sup>316</sup> TGW (n=95, 23/39 countries), and TGM (n=5, 5/39 countries).
- For ART coverage, 621 observations were identified. After processing, 259
- observations were extracted from 62 studies. Denominators were available for 98%
- (254/259). Data were most available for FSW (n=135, 27/39 countries), followed by

320	MSM (n=92, 24/39), TGW (n=17, 10/39 countries), and PWID (n=15, 8/39 countries).
321	No data were available for TGM. Fifty-nine percent of observations were VLS [152/259],
322	9% ART metabolite testing [24/259], and 32% self-reported ART usage [83/259].
323	We estimated that, across countries, a median 1.65% of urban cisgender women aged
324	15-49 years were FSW (interquartile range [IQR] 1.35-1.91), 0.89% of men had sex with
325	men (IQR 0.77-0.95), 0.32% of men injected drugs (IQR 0.31-0.34), and 0.10% of
326	women were transgender (IQR 0.06-0.12; Figure 2). Incorporating the rural-to-urban
327	ratio, median proportions of national total populations were 1.19% FSW, 0.66% MSM,
328	0.25% PWID, and 0.08% TGW. In sensitivity analysis using age 15-29 years as a
329	denominator for MSM PSEs and 15-39 years for FSW PSEs, median urban proportions
330	for MSM were 1.36% (IQR 1.15-1.42) and for FSW were 1.82% (IQR 1.60-2.13)
331	(Supplementary Figure S3).
332	Urban KPSE proportions were higher in ESA than WCA among FSW (median
333	difference +0.3%; 95% credible interval [CrI] -0.3, 1.0) and MSM (+0.2%; 95%CrI -0.2,
334	0.5) but uncertainty ranges contained zero. Proportions were similar between regions
335	among PWID and TGW, but KPSE data were sparse overall. PSE proportions derived
336	from PLACE and mapping studies were significantly lower than those derived from other
337	methods among FSW (odds ratio 0.58; 95%Crl 0.40, 0.83), MSM (0.26; 95%Crl 0.17,
338	0.41), and PWID (0.31; 95%CrI 0.19, 0.53), and lower among TGW (0.27; 95%CrI 0.07,

- 1.11) but for TGW the 95% credible interval contained 1 (Supplementary Table S4;
- <sup>340</sup> Supplementary Figure S4; Supplementary Tables S9-S12).

Observed HIV prevalence among key populations was consistently higher than area-341 matched total population HIV prevalence. Logit key population HIV prevalence in ESA 342 was more strongly correlated with matched logit total population HIV prevalence than in 343 WCA (Figure 3). In ESA, 15% population prevalence corresponded to 53% (95%Crl 45, 344 62) HIV prevalence among FSW, 21% (95%Crl 12, 31) among MSM, 28% (95%Crl 15, 345 45) among PWID, and 22% (95%Crl 14, 34) among TGW. In WCA, relative patterns 346 were similar, but key population HIV prevalence varied less with total population HIV 347 prevalence than in ESA. HIV prevalence differentials between key population and total 348 population were larger when population prevalence was lower (Figure 3C). 349 Supplementary Table S5-S7 report regression results, Supplementary Table S13 350 reports country-specific estimates, and Supplementary Figure S5 reports sensitivity 351 analysis of imputed tested denominators. 352 ART coverage among FSW, MSM, PWID, and TGW was correlated with gender-353 matched population ART coverage, but with wide heterogeneity in relative ART 354 coverage across studies (Figure 4). At 80% population coverage, predicted ART 355 coverage among FSW was 11% lower (95%Crl 19, 4%), 19% lower (30, 10%) among 356 MSM, 25% lower (41, 11%) among PWID, 13% lower (43, 18%) among TGW. 357

Supplementary Table S8 reports regression results and S14 reports country-specific
 estimates.

In sensitivity analysis including a fixed effect for ART measurement method, self reported ART coverage was lower than lab-determined ART, but with wide 95% credible
 interval spanning no difference (odds ratio 0.73, 95%Crl 0.47, 1.15; Supplementary

363	Figure S6, Table S8). Assuming MSM surveys represented MSM aged 15-29 years or
364	FSW surveys represented FSW aged 15-39 years minimally affected on HIV prevalence
365	or ART coverage estimates (Supplementary Table S16).

- Across SSA, FSW, MSM, PWID, and TGW combined were 1.2% (95%Crl 0.9, 1.6) of
- the population aged 15-49 years (3.7m FSW, 1.9m MSM, 770,000 PWID, and 230,000
- TGW), but 6.1% (95%Crl 4.5, 8.2) of PLHIV aged 15-49 years. In ESA this was 4.9%
- (95%Crl 3.4, 6.9) of PLHIV compared to 1.3% (95%Crl 0.9, 1.8) of the population and,
- in WCA, 11.7% (95%Crl 8.3, 16.5) of PLHIV compared to 1.2% (95%Crl 0.9, 1.7) of the
- population. FSW were 4.0% (95%Crl 2.7, 5.7) of PLHIV in SSA (750,000 PLHIV;
- 372 95%Crl 520,000, 1,100,000), MSM were 1.4% (95%Crl 0.9, 2.0) or 250,000 PLHIV
- 373 (95%Crl 170,000, 380,000), PWID were 0.5% (95%Crl 0.3, 0.8) or 89,000 PLHIV
- 374 (95%Crl 50,000, 150,000), and TGW were 0.2% (95%Crl 0.1, 0.5) or 44,000 PLHIV
- 375 (95%Crl 20,000, 100,000) (Figure 5).

### 376 **Discussion**

- 377 Data from 273 key population surveys provided consistent evidence across sub-
- <sup>378</sup> Saharan Africa of higher HIV prevalence and lower ART coverage among key
- populations. We estimated there are 3.7 million FSW, 1.9 million MSM, 770,000 PWID,
- and 230,000 TGW in SSA who require comprehensive HIV prevention or treatment
- services. HIV prevalence was estimated to be 21% among FSW, 14% among MSM,
- <sup>382</sup> 11% among PWID, and 20% among TGW. These were 4.6, 5.9, 4.6, and 4.4 times
- <sup>383</sup> higher than adult population prevalence, respectively, with larger relative differences
- <sup>384</sup> when population prevalence was lower. Together, key populations constituted 1.2% of

the adult population in SSA but 6.1% of PLHIV. ART coverage among key populations
increased with total population coverage, but lagged behind at high population ART
coverage levels. However, there was wide uncertainty about estimates aggregated
within countries and across SSA.

This exercise highlighted major data gaps and challenges interpreting existing data. 389 Across the twelve combinations of three indicators and four key populations analysed 390 here, on average countries had data for seven combinations (Supplementary Table S3). 391 Data gaps are larger when restricting to the highest guality and most recent data. These 392 gaps impede planning for equitable and universal access to HIV services and will 393 persist without firm commitments to collect key population survey data. Implementation 394 of high-quality surveys will also require addressing entrenched discriminatory practices 395 and punitive laws and policies against key populations<sup>3,41–43</sup> In settings lacking or with 396 limited data, our extrapolated estimates can be a foundation with which to guide future 397 surveillance priorities, stimulate in-country data review and use, and estimate HIV 398 epidemic indicators. Future efforts should especially focus on strengthening surveillance 399 for MSM, PWID, and transgender people, and supporting use of HIV service delivery 400 data for all key populations, while ensuring the safety and protection of marginalised 401 individuals and their communities.<sup>3</sup> 402

Previous key population reviews and meta-analyses<sup>11,44–46</sup> relied on systematic
searches of peer-reviewed literature. Our initial sources were existing databases,
primarily populated by surveillance teams in each country or implementing
organisations. This resulted in including a larger grey literature body, such as survey

reports, which are infrequently indexed by peer-reviewed databases.<sup>47</sup> However, many 407 observations from initial databases could not be validated in source documents and 408 were excluded from analysis, which in some countries excluded the only reported data. 409 Demand for total population HIV estimates in SSA has promoted high-quality 410 comparable surveillance methods, documentation, and dissemination. Review of key 411 population data by national HIV surveillance teams was introduced into the UNAIDS 412 sub-Saharan African estimates process in 2022, providing context for existing surveys, 413 identifying missing sources and adding new data. This, alongside ongoing key 414 population data initiatives and concerted advocacy efforts that ensure public 415 dissemination, will improve the foundation for HIV surveillance among key populations 416 and promote parity for key populations within national HIV data and strategic 417 information. 418

Systematically collated data on key population size, HIV prevalence, and ART coverage 419 are critical inputs for mathematical modelling analyses that guide optimal HIV resource 420 allocation. Such studies consistently demonstrate that fully meeting the HIV prevention 421 and treatment needs of key populations would be impactful on reducing overall 422 population incidence due to network effects of averting further onward transmission over 423 time and to non-key population partners.<sup>48,49</sup> Model-based counterfactual indicators that 424 capture these impacts, such as the transmission preventable attributable fraction, are a 425 better basis for intervention prioritisation than simple population proportions reported in 426 survey data.48,50,51 427

Our estimates that 0.29% of men in SSA injected drugs was lower than recent 428 estimates from Degenhardt et al. of 0.38%, though uncertainty ranges overlapped.<sup>22</sup> 429 This may reflect incorporating the urban-to-rural ratio in national PSE extrapolation in 430 this analysis. We estimated that 1.2% of women aged 15-49 years sold sex, similar to 431 the 1.1% estimated by Laga *et al.*<sup>52</sup> Our finding of heterogeneous HIV prevalence ratios 432 between MSM and the total population was consistent with Hessou et al.,<sup>53</sup> particularly 433 in WCA where HIV burden in neighbouring countries can vary considerably. Our 434 estimate of 57% ART coverage among MSM in 2022 was lower than 73% from a meta-435 analysis by Stannah et al.<sup>54</sup> of studies conducted up to 2022, with overlapping 436 uncertainty. This may be due to exclusion of ART coverage using self-reported HIV 437 status in this analysis. 438

Population size estimates measured in the same population at different times or with 439 multiple methods were highly heterogenous, limiting data use for establishing 440 meaningful programmatic targets or monitoring temporal trends. Very large uncertainty 441 ranges around population size and PLHIV modelled estimates were consistent with 442 findings of other statistically summarised and extrapolated PSE from multiple 443 sources.<sup>55–58</sup> Non-existence of rural KPSE studies to empirically inform rural-urban 444 population proportions contributed to five-fold or greater relative uncertainty in 445 extrapolated national estimates. Moreover, quality assessments of individual KPSE 446 studies were not conducted as part of this analysis. Both systematically improving and 447 evaluating study-specific implementation guality and methodological assumptions may 448 reduce heterogeneity and increase the utility of KPSE data.<sup>59–63</sup> 449

Seventy-two percent of MSM KPSE observations and 38/39 modelled urban MSM 450 estimates were below 1% of the male adult (15-49 years) population which UNAIDS and 451 WHO recommended in 2020 as a minimum MSM population proportion.<sup>64</sup> The minimum 452 threshold was specified to ensure that MSM were not overlooked due to lack of data. 453 Variation in MSM proportions measured in PSE studies may reflect ability to engage in 454 sexual behaviours or surveys, affected by legal and social environment and other 455 factors, rather than differences in distribution of sexual preference. It is also uncertain 456 whether MSM recruited in surveys, who are disproportionately young,<sup>12,13</sup> are 457 representative of the total MSM population. Specifying a minimum 1% threshold for 458 MSM population could result in unrealistic MSM-focused service targets. The threshold 459 should be reconsidered with the wider range of population size and stigma data now 460 available, aligned with risk-based approaches to quantifying sex work and injecting drug 461 use. Study-specific quality assessments will be important to producing accurate KPSE 462 given stigma experienced by MSM in many settings. 463

Integrating key population programme data within key population estimates should be a 464 priority to improve utility of surveillance data to guide programmatic response and 465 monitor trends and subnational variation.<sup>65</sup> Triangulating routine HIV testing and 466 treatment data with biobehavioural survey data may help disentangle programmatic 467 double counting, coverage of key population-specific services, and accounting for 468 linkage to care in the estimation of ART coverage and viral load suppression.<sup>66–68</sup> 469 Future surveillance should consider moving beyond strictly defined key population 470 definitions accurately to reflect heterogenous risks among individuals in overlapping risk 471

environments including cisgender MSM and transgender women who sell sex, and FSW
 and MSM who inject drugs.<sup>69–71</sup>

Several limitations should be considered when interpretating these data and estimates. 474 Firstly, surveys used a range of key population definitions and inclusion criteria which 475 limited comparability, though there was sufficient overlap (Supplementary Text S2). 476 Second, lack of explicit geographic survey sampling frames made it challenging to 477 reflect the catchment population for a given survey in matched denominators. 478 particularly given the mobility of key populations.<sup>72</sup> This likely exacerbates the observed 479 heterogeneity in KPSE proportions (Figure 2B), and is a major limitation for 480 extrapolating KPSE proportions for programmatic planning. Going forward, specification 481 of population catchments and careful data quality assessments to determine study 482 inclusion and interpretation will improve future data use. Third, sample size or standard 483 errors and age ranges were omitted from most population size data entries, gender was 484 not specified for most observations among PWID, and a small number of observations 485 were missing denominators for number tested. This limited ability to statistically weight, 486 age-standardise, or gender-match data in model extrapolations, though sensitivity 487 analyses indicate little impact on analysis conclusions. Fourth, data were insufficient 488 and too heterogeneous to estimate time trends in population proportions, HIV 489 prevalence, or ART coverage. Application of standardised recruitment methods, 490 population definitions, and indicator reporting in consistent locations will improve 491 monitoring of trends. Finally, this analysis did not include prisoners and other 492 incarcerated people and future studies should look to expand data synthesis and 493 analysis to this key population. 494

In conclusion, key populations across SSA experience disproportionate HIV burden and 495 have lower antiretroviral therapy coverage. Consolidated key population data and 496 synthesised estimates provide a basis for key population programming in all countries, 497 including those with limited locally available data. Despite increasing focus on key 498 populations in HIV/AIDS strategies in SSA, large data gaps remain and estimates are 499 highly uncertain. New surveillance strategies, improved use of routine data, and more 500 consistent surveillance implementation are required to furnish more precise estimates 501 and trends for programme planning and support the monitoring of equitable and equal 502 access to HIV prevention and treatment programmes outlined in the Global AIDS 503 Strategy 2021-2026. 504

# 505 Authors' contributions

- OS, KS, MM and JWI-E conceptualised the study. KS, SAG, JZ, AMcI, KW, JS, LD
- <sup>507</sup> curated key population survey databases. OS, RA, EG, AS-B reviewed primary source
- documents, deduplicated data, and extracted data. OS analysed the data and wrote the
- <sup>509</sup> first draft of the manuscript. All authors contributed to interpretation of results and edited
- the manuscript for intellectual content. All authors read and approved the final version of
- the manuscript for submission.

## 512 **Disclaimer**

<sup>513</sup> The findings and conclusions in this report are those of the author(s) and do not

necessarily represent the official position of the funding agencies.

#### 515 **Conflict of interest**

- 516 SB acknowledges funding from the National Institutes of Health (NIH); FC
- acknowledges funding from Wellcome Trust, MRC, NIH, UNITAID, and the Bill and
- 518 Melinda Gates Foundation (BMGF); LD has received untied educational grants for the
- study of new opioid medications in Australia from Indivior and Sequirus; LF
- acknowledges funding from the UKRI Medical Research Council, the Royal Society, and
- from the Centre for Sexual Health and HIV/AIDS Research Zimbabwe; JI-E
- acknowledges funding from UNAIDS, NIH, BMGF, UKRI, and BAO Systems, and
- received support to attend meetings from UNAIDS, the South African Centre for
- 524 Epidemiological Modelling and Analysis, the International AIDS Society, and BMGF; KR

- and MM-G received support to attend meetings from UNAIDS; JS acknowledges
- <sup>526</sup> funding from UNAIDS; OS acknowledges funding from UNAIDS.

### 527 Data sharing

- 528 Data extracted and code to reproduce the analysis are available at
- 529 https://zenodo.org/records/10838438.

## 530 Acknowledgments

- <sup>531</sup> This research was supported by UNAIDS, Bill and Melinda Gates Foundation (INV-
- <sup>532</sup> 006733), National Institute of Allergy and Infectious Disease of the National Institutes of
- Health under award number R01AI136664, and the MRC Centre for Global Infectious
- 534 Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical
- Research Council (MRC) and the UK Foreign, Commonwealth & Development Office
- (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2
- <sup>537</sup> programme supported by the European Union. MM-G's research program is funded by
- a Canada Research Chair (Tier II) in Population Health Modeling.

# 539 **References**

- 1. UNAIDS. *The Gap Report.*; 2014. Accessed April 1, 2022.
- 541 https://www.unaids.org/en/resources/documents/2014/20140716\_UNAIDS\_gap\_r
- 542 eport
- Garnett GP. Reductions in HIV incidence are likely to increase the importance of
   key population programmes for HIV control in sub Saharan Africa. *J Int AIDS* Soc. 2021;24(S3):e25727. doi:10.1002/jia2.25727
- 3. World Health Organization. Consolidated Guidelines on HIV, Viral Hepatitis and
- 547 STI Prevention, Diagnosis, Treatment and Care for Key Populations.; 2022.
- <sup>548</sup> http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431\_eng.pdf?ua=1
- 4. United Nations. End Inequalities. End AIDS. Global AIDS Strategy 2021-2026 |
   UNAIDS. Published 2021. Accessed May 5, 2021.
- https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS strategy
- 5. Baneshi MR, Rastegari A, Haghdoost AA. Review of Size Estimation Methods. In:
  Advances in Experimental Medicine and Biology. Vol 1333. Springer; 2021:1-15.
  doi:10.1007/978-3-030-75464-8\_1
- 556 6. Abdul-Quader AS, Baughman AL, Hladik W. Estimating the size of key
- <sup>557</sup> populations: Current status and future possibilities. *Curr Opin HIV AIDS*.
- <sup>558</sup> Published online 2014. doi:10.1097/COH.000000000000041

559	7.	Jin H, Restar A, Beyrer C. Overview of the epidemiological conditions of HIV
560		among key populations in Africa. J Int AIDS Soc. 2021;24(S3).
561		doi:10.1002/jia2.25716
562	8.	Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the
563		key population cascade through surveys and services to guide the HIV response.
564		J Int AIDS Soc. 2018;21(Suppl Suppl 5):e25119. doi:10.1002/jia2.25119
565	9.	Sabin K, Zhao J, Garcia Calleja JM, et al. Availability and quality of size
566		estimations of female sex workers, men who have sex with men, people who
567		inject drugs and transgender women in low- and middle-income countries. PLoS
568		<i>One</i> . 2016;11(5). doi:10.1371/journal.pone.0155150
569	10.	Atuhaire L, Adetokunboh O, Shumba C, Nyasulu PS. Effect of community-based
570		interventions targeting female sex workers along the HIV care cascade in sub-
571		Saharan Africa: a systematic review and meta-analysis. Syst Rev. Published
572		online 2021. doi:10.1186/s13643-021-01688-4
573	11.	Baral S, Beyrer C, Muessig K, et al. Burden of HIV among female sex workers in
574		low-income and middle-income countries: A systematic review and meta-analysis.
575		Lancet Infect Dis. Published online 2012. doi:10.1016/S1473-3099(12)70066-X
576	12.	Stannah J, Dale E, Elmes J, et al. HIV testing and engagement with the HIV
577		treatment cascade among men who have sex with men in Africa: a systematic
578		review and meta-analysis. Lancet HIV. 2019;6(11):e769-e787.
579		doi:10.1016/S2352-3018(19)30239-5

580	13.	Stannah J, Soni N, Keng J, et al. Trends in HIV testing, the treatment cascade,
581		and HIV incidence among men who have sex with men in Africa: A systematic
582		review and meta-regression analysis. Lancet HIV. Published online 2023.
583		doi:0.1016/S2352-3018(23)00111-X
584	14.	Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug
585		use and HIV among people who inject drugs: a systematic review. The Lancet.
586		Published online 2008. doi:10.1016/S0140-6736(08)61311-2
587	15.	Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug
588		use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV
589		in people who inject drugs: a multistage systematic review. Lancet Glob Health.
590		2017;5(12):e1192-e1207. doi:10.1016/S2214-109X(17)30375-3
591	16.	Kloek M, Bulstra CA, van Noord L, Al-Hassany L, Cowan FM, Hontelez JAC. HIV
592		prevalence among men who have sex with men, transgender women and
593		cisgender male sex workers in sub-Saharan Africa: a systematic review and
594		meta-analysis. J Int AIDS Soc. 2022;25(11). doi:10.1002/JIA2.26022
595	17.	Stevens O. HIV prevalence in transgender populations and cisgender men who
596		have sex with men in sub-Saharan Africa 2010-2022: a meta-analysis. medRxiv.
597		Published online 2023. doi:10.1101/2023.11.09.23298289
598	18.	UNAIDS. Global AIDS Monitoring 2022. Published 2022. Accessed February 18,
599		2022. https://www.unaids.org/en/global-aids-monitoring

600	19.	UNAIDS, WHO. Recommended Population Size Estimates for Men Who Have
601		Sex with Men.; 2020.

- Rao A, Schwartz S, Sabin K, et al. HIV-related data among key populations to
   inform evidence-based responses: protocol of a systematic review. *Syst Rev.* Published online 2018.
- <sup>605</sup> 21. UNAIDS, FHI 360, WHO, CDC, PEPFAR. *Biobehavioural Survey Guidelines For*

606 Populations At Risk For HIV.; 2017. Accessed February 17, 2022.

- 607 http://apps.who.int/bookorders.
- 22. Degenhardt L, Webb P, Colledge-Frisby S, et al. Epidemiology of injecting drug
- <sup>609</sup> use, prevalence of injecting-related harm, and exposure to behavioural and
- environmental risks among people who inject drugs: a systematic review. *Lancet*
- Glob Health. 2023;11(5):e659-e672. doi:10.1016/S2214-109X(23)00057-8
- 23. UNAIDS. Global AIDS Monitoring 2022. Published 2022. Accessed February 18,
- 613 2022. https://www.unaids.org/en/global-aids-monitoring
- <sup>614</sup> 24. UNAIDS. Key Populations Atlas. Accessed November 27, 2021.
- 615 https://kpatlas.unaids.org/dashboard
- <sup>616</sup> 25. Rao A, Schwartz S, Sabin K, et al. HIV-related data among key populations to
- inform evidence-based responses: protocol of a systematic review. *Syst Rev.*
- 618 Published online 2018.

619	26.	UNAIDS. HIV sub-national estimates viewer. Published 2021. Accessed May 12,
620		2022. https://naomi-spectrum.unaids.org/
621	27.	Eaton JW, Dwyer-Lindgren L, Gutreuter S, et al. Naomi: a new modelling tool for
622		estimating HIV epidemic indicators at the district level in sub-Saharan Africa. J Int
623		AIDS Soc. Published online 2021. doi:10.1002/jia2.25788
624	28.	Global Rural-Urban Mapping Project (GRUMP). Urban boundaries. Accessed
625		October 25, 2021. https://sedac.ciesin.columbia.edu/data/collection/grump-v1
626	29.	Neal JJ, Prybylski D, Sanchez T, Hladik W. Population size estimation methods:
627		Searching for the holy grail. JMIR Public Health Surveill. Published online 2020.
628		doi:10.2196/25076
629	30.	Eaton JW, Brown T, Puckett R, et al. The Estimation and Projection Package
630		Age-Sex Model and the r-hybrid model: New tools for estimating HIV incidence
631		trends in sub-Saharan Africa. AIDS. 2019;33(Suppl 3):S235-S244.
632		doi:10.1097/QAD.000000000002437
633	31.	Johnson LF, Kariminia A, Trickey A, et al. Achieving consistency in measures of
634		HIV-1 viral suppression across countries: derivation of an adjustment based on
635		international antiretroviral treatment cohort data. J Int AIDS Soc. 2021;24 Suppl
636		5(Suppl 5). doi:10.1002/JIA2.25776
637	32.	Nations U, of Economic D, Affairs S, Division P. World Urbanization Prospects
638		The 2018 Revision.; 2018.

639	33.	Maleke K, Makhakhe N, Peters RPH, et al. HIV risk and prevention among men
640		who have sex with men in rural South Africa. African Journal of AIDS Research.
641		2017;16(1):31-38. doi:10.2989/16085906.2017.1292925
642	34.	Wimark T. The City as a Single Gay Male Magnet? Gay and Lesbian
643		Geographical Concentration in Sweden. 2014;752(September 2013):739-752.
644	35.	Kobrak P, Ponce R, Zielony R. New Arrivals to New York City : Vulnerability to
645		HIV among Urban Migrant Young Gay Men. Arch Sex Behav. Published online
646		2015:2041-2053. doi:10.1007/s10508-015-0494-4
647	36.	Johnson LF, Mulongeni P, Marr A, Lane T. Age bias in survey sampling and
648		implications for estimating HIV prevalence in men who have sex with men:
649		Insights from mathematical modelling. Epidemiol Infect. 2018;146(8):1036-1042.
650		doi:10.1017/S0950268818000961
651	37.	Stannah J, Dale E, Elmes J, et al. HIV testing and engagement with the HIV
652		treatment cascade among men who have sex with men in Africa: a systematic
653		review and meta-analysis. Lancet HIV. 2019;6(11):e769-e787.
654		doi:10.1016/S2352-3018(19)30239-5
655	38.	Jones HS, Anderson RL, Cust H, et al. HIV incidence among women engaging in
656		sex work in sub-Saharan Africa: a systematic review and meta-analysis. medRxiv.
657		Published online January 1, 2023:2023.10.17.23297108.
658		doi:https://doi.org/10.1101/2023.10.17.23297108

659	39.	UNAIDS. Global AIDS Update. Published 2021. Accessed May 12, 2022.
660		https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update
661	40.	Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent
662		Health Estimates Reporting: the GATHER statement. The Lancet.
663		2016;388(10062):e19-e23. doi:10.1016/S0140-6736(16)30388-9
664	41.	Lyons C, Bendaud V, Bourey C, et al. Global assessment of existing HIV and key
665		population stigma indicators: A data mapping exercise to inform country-level
666		stigma measurement. PLoS Med. 2022;19(2):e1003914.
667		doi:10.1371/JOURNAL.PMED.1003914
668	42.	UNAIDS. Prevailing against pandemics by putting people at the centre. Published
669		online 2020.
670	43.	HIV Policy Lab. HIV Policy Lab. Accessed October 25, 2023.
671		https://www.hivpolicylab.org/
672	44.	Hessou PHS, Glele-Ahanhanzo Y, Adekpedjou R, et al. Comparison of the
673		prevalence rates of HIV infection between men who have sex with men (MSM)
674		and men in the general population in sub-Saharan Africa: A systematic review
675		and meta-analysis. BMC Public Health. 2019;19(1):1634. doi:10.1186/s12889-
676		019-8000-x

677	45.	Stutterheim SE, Van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in
678		transgender individuals: An updated systematic review and meta-analysis. PLoS
679		One. 2021;16(12 December). doi:10.1371/journal.pone.0260063
680	46.	Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug
681		use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV $$
682		in people who inject drugs: a multistage systematic review. Lancet Glob Health.
683		2017;5(12):e1192-e1207. doi:10.1016/S2214-109X(17)30375-3
684	47.	Stevens O. HIV prevalence in transgender populations and cisgender men who
685		have sex with men in sub-Saharan Africa 2010-2021: a meta-analysis. Published
686		online 2022.
687	48.	Stone J, Mukandavire C, Boily M, et al. Estimating the contribution of key
688		populations towards HIV transmission in South Africa. J Int AIDS Soc.
689		2021;24(1):e25650. doi:10.1002/jia2.25650
690	49.	Mishra S, Pickles M, Blanchard JF, Moses S, Boily MC. Distinguishing sources of
691		HIV transmission from the distribution of newly acquired HIV infections: Why is it
692		important for HIV prevention planning? Sex Transm Infect. 2014;90(1):19-25.
693		doi:10.1136/sextrans-2013-051250
694	50.	Mishra S, Pickles M, Blanchard JF, Moses S, Shubber Z, Boily MC. Validation of
695		the modes of transmission model as a tool to prioritize HIV prevention targets: A
696		comparative modelling analysis. PLoS One. 2014;9(7).
697		doi:10.1371/journal.pone.0101690

698	51.	Shubber Z, Mishra S, Vesga JF, Boily MC. The HIV modes of transmission model:
699		A systematic review of its findings and adherence to guidelines. J Int AIDS Soc.
700		2014;17(1). doi:10.7448/IAS.17.1.18928
701	52.	Laga I, Niu X, Rucinski K, et al. Mapping the Population Size of Female Sex
702		Worker in Countries Across Sub-Saharan Africa. PNAS. Published online
703		September 19, 2023. doi:10.1073/pnas.2200633120
704	53.	Hessou PHS, Glele-Ahanhanzo Y, Adekpedjou R, et al. Comparison of the
705		prevalence rates of HIV infection between men who have sex with men (MSM)
706		and men in the general population in sub-Saharan Africa: A systematic review
707		and meta-analysis. BMC Public Health. 2019;19(1):1634. doi:10.1186/s12889-
708		019-8000-x
709	54.	Stannah J, Dale E, Elmes J, et al. HIV testing and engagement with the HIV
710		treatment cascade among men who have sex with men in Africa: a systematic
711		review and meta-analysis. Lancet HIV. Published online 2019.
712		doi:10.1016/S2352-3018(19)30239-5
713	55.	Edwards JK, Hileman S, Donastorg Y, et al. Estimating Sizes of Key Populations
714		at the National Level: Considerations for Study Design and Analysis.
715		Epidemiology. 2018;29(6):795-803. doi:10.1097/EDE.00000000000000906
716	56.	Niu XM, Rao A, Chen D, et al. Using factor analyses to estimate the number of
717		female sex workers across Malawi from multiple regional sources. Ann Epidemiol.
718		2021;55:34-40. doi:10.1016/j.annepidem.2020.12.001
		35

- 57. Fearon E, Chabata ST, Magutshwa S, et al. Estimating the Population Size of
- 720 Female Sex Workers in Zimbabwe: Comparison of Estimates Obtained Using
- 721 Different Methods in Twenty Sites and Development of a National-Level Estimate.
- <sup>722</sup> J Acquir Immune Defic Syndr. 2020;85(1):30-38.
- 723 doi:10.1097/QAI.00000000002393
- 58. Datta A, Lin W, Rao A, et al. Bayesian Estimation of MSM Population Size in Côte
- d'Ivoire. *Statistics and Public Policy*. 2019;6(1):1-13.
- <sup>726</sup> doi:10.1080/2330443X.2018.1546634
- 59. Wesson PD, Mirzazadeh A, McFarland W. A Bayesian approach to synthesize
- restimates of the size of hidden populations: The anchored multiplier. Int J

*Epidemiol.* 2018;47(5):1636-1644. doi:10.1093/ije/dyy132

- 60. Fellows I. Consensus Estimate Calculator. Accessed April 11, 2022.
- 731 https://epiapps.com/shiny/app\_direct/shinyproxy\_combine\_estimates/
- 61. USAID. Namibia Small Area Estimation: Final Report Small Area Estimation of
- 733 Key Population Sizes in Namibia: Final Report.; 2021.
- 62. Datta A, Lin W, Rao A, et al. Bayesian Estimation of MSM Population Size in Côte
- <sup>735</sup> d'Ivoire. *Statistics and Public Policy*. 2019;6(1):1-13.
- 736 doi:10.1080/2330443X.2018.1546634
- 737 63. Rao A, Schwartz S, Viswasam N, et al. Evaluating the quality of HIV
- epidemiologic evidence for populations in the absence of a reliable sampling

- frame: a modified quality assessment tool. *Ann Epidemiol*. 2022;65:78-83.
- 740 doi:10.1016/J.ANNEPIDEM.2021.07.009
- 64. UNAIDS, WHO. Recommended Population Size Estimates for Men Who Have
  Sex with Men.; 2020.
- <sup>743</sup> 65. USAID. Namibia Small Area Estimation: Final Report Small Area Estimation of
   <sup>744</sup> Key Population Sizes in Namibia: Final Report.; 2021.

66. Scheibe AP. Still left behind: Using programmatic data to assess harm reduction
service coverage and HIV treatment cascades for people who inject drugs in five
South African cities. In: *IAS*. ; 2019.

<sup>748</sup> 67. Scheibe A, Grasso M, Raymond HF, et al. Modelling the UNAIDS 90-90-90

treatment cascade for gay, bisexual and other men who have sex with men in

750 South Africa: using the findings of a data triangulation process to map a way


<sup>751</sup> forward. *AIDS Behav.* 2018;22(3):853-859. doi:10.1007/s10461-017-1773-y

- Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the
  key population cascade through surveys and services to guide the HIV response. *J Int AIDS Soc.* 2018;21(Suppl Suppl 5):e25119. doi:10.1002/jia2.25119
- 69. Syvertsen JL, Agot K, Ohaga S, Bazzi AR. You can't do this job when you are
- sober: Heroin use among female sex workers and the need for comprehensive
- <sup>757</sup> drug treatment programming in Kenya. *Drug Alcohol Depend*. 2019;194:495-499.
- <sup>758</sup> doi:10.1016/j.drugalcdep.2018.10.019

759	70.	Poteat T, Ackerman B, Diouf D, et al. HIV prevalence and behavioral and
760		psychosocial factors among transgender women and cisgender men who have
761		sex with men in 8 African countries: A cross-sectional analysis. PLoS Med.
762		Published online 2017. doi:10.1371/journal.pmed.1002422
763	71.	Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide
764		burden of HIV in transgender women: A systematic review and meta-analysis.
765		Lancet Infect Dis. 2013;13(3):214-222. doi:10.1016/S1473-3099(12)70315-8
766	72.	Davey C, Dirawo J, Mushati P, Magutshwa S, Hargreaves JR, Cowan FM.
767		Mobility and sex work: why, where, when? A typology of female-sex-worker
768		mobility in Zimbabwe. Soc Sci Med. 2019;220:322-330.
769		doi:10.1016/j.socscimed.2018.11.027

770

# 772 Figures and Tables



773

Figure 1: Flow diagrams describing identified data for key population size estimates, HIV prevalence
data, and key population ART coverage. Each *n* represents number of population/method/location
observations, with potentially observations for multiple subnational locations from the same study in same
country. ART: Antiretroviral therapy coverage; FSW: Female sex worker; MSM: Men who have sex with
men; PWID: People who inject drugs; TGW: Transgender women; KP: Key Population; GAM: Global
AIDS Monitoring; CDC: US Centers for Disease Control and Prevention; PSE: Population size estimate.

Table 1: Availability of population size, HIV prevalence, and ART coverage data by key
 population and region during period 2010-2023.


783


	Key	Key Population Size Estimates		HIV prevalence		ART coverage	
Region	population	Data- points	Countries with data (n; %)	Data- points	Countries with data (n; %)	Data- points	Countries with data (n; %)
	FSW	972	35 (90)	559	36 (92)	135	27 (69)
SSA	MSM	647	33 (85)	370	34 (87)	92	24 (62)
(39	PWID	329	23 (59)	159	21 (54)	15	8 (21)
countries)	TGW	117	13 (33)	95	23 (59)	17	10 (26)
	TGM	16	2 (5)	5	5 (13)	0	0 (0)
	FSW	450	17 (94)	236	18 (100)	85	14 (78)
ESA	MSM	291	15 (83)	127	15 (83)	45	12 (67)
(18	PWID	156	8 (44)	52	9 (50)	10	5 (28)
countries)	TGW	65	7 (39)	38	12 (67)	13	7 (39)
	TGM	16	2 (11)	2	2 (11)	0	0 (0)
	FSW	522	18 (86)	323	18 (86)	50	13 (62)
WCA	MSM	356	18 (86)	243	19 (90)	47	12 (57)
(21	PWID	173	15 (71)	107	12 (57)	5	3 (14)
countries)	TGW	52	6 (29)	57	11 (52)	4	3 (14)
	TGM	0	0 (0)	3	3 (14)	0	0 (0)

784 SSA: Sub-Saharan Africa; ESA: East and Southern Africa; WCA: Western and Central Africa; FSW:

female sex workers; MSM: men who have sex with men; PWID: people who inject drugs; TGW:

transgender women; TGM: transgender men; ART: antiretroviral therapy





787

Country has local surveillance data — No — Yes

Figure 2: Model estimated urban key population size estimate (KPSE) proportions for female sex
 workers, men who have sex with men, people who inject drugs, and transgender women as a proportion
 of gender-matched 15-49 years adult total population. (A) Posterior median estimate for each country.
 Note: colour range is different for each key population chloropleth. (B) Posterior median estimate and


<sup>792</sup> 95% credible intervals for each country. Points represent observations of subnational KPSE proportions

that used empirical methods. Countries that had local surveillance data are shown in blue, and countries

informed only by spatial smoothing from neighbouring countries in yellow. Vertical axis shown on log-


scale.

medRxiv preprint doi: https://doi.org/10.1101/2022.07.27.22278071; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



796


Figure 3: Key population and total population HIV prevalence on the logit scale (A), natural scale (B), and 797 expressed as a ratio of key population and total population prevalence (C) for female sex workers, men 798 who have sex with men, people who inject drugs, and transgender women. Coloured points indicate 799 observed key population prevalence plotted against gender/year/province-matched total population 800 prevalence. Logit-scale regional correlation coefficients and 95%Crl uncertainty intervals shown in 801 coloured text in panel A. Coloured lines and shading represent regional estimate and 95% uncertainty 802 803 results. Points represent country estimates [filled for countries with HIV prevalence data and empty for countries without HIV prevalence data] and 95% uncertainty ranges. Dotted line represents line of 804 equality. 805



806 807

**Figure 4:** Estimated key population ART coverage as a function of total population ART coverage on the estimated logit scale (upper) and natural scale (lower). Coloured points indicate observed key population prevalence plotted against gender/year/province-matched total population ART coverage. Logit-scale correlation coefficients and 95%Crl uncertainty intervals shown in panel A. Black line and shading represent estimate for sub-Saharan Africa and 95% uncertainty results. Black points represent country

estimates and 95% uncertainty ranges. Dotted line represents line of equality.



- **Figure 5:** (A) HIV positive key population members as a proportion of all PLHIV aged 15-49 years.
- 817 Countries are ordered geographically. (B) Estimated number of key populations living with HIV (KPLHIV)
- in Eastern and Southern Africa and Western and Central Africa.